I-O Market Heats Up the Summer of 2017: Merck gaining on BMS Share

The fast passed I-O market continues to heat up. New June market share data from Symphony Health shows Keytruda gaining 4 percentage points bringing it up to a 32% share. Opdivo remains the leader but dropped from 64% to 61% share. Roche’s Tecentriq remained steady at 7% market share. This fast growing market has been the lead story since 2014 when Keytruda gain first IO approval in advanced melanoma. BMS quickly joined the fun with Opdivo shortly after with its own advanced melanoma indication but took the lead when it gain approval for advanced NSCLC. The impact of these important therapies is just beginning to make itself known. PhRMA reported this week that there are over 4000 oncology projects in clinical development. Combination strategies with these I-O leaders are being employed by numerous companies with over 560 clinical trials with Opdivo and Keytruda alone. With CAR-T therapies on the verge of approval, the immunotherapy market will continue to be a news leader.